...
首页> 外文期刊>Cancers >Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis
【24h】

Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis

机译:肝切除术后的随访肝硬度测量影响与乙型肝炎相关的肝细胞癌合并肝硬化的肿瘤学结果

获取原文
           

摘要

The severity of liver fibrosis can be noninvasively evaluated by measuring liver stiffness (LS) using transient elastography. This study aimed to evaluate the prognostic value of achieving low liver stiffness measurement (LSM) in patients with cirrhosis confirmed from the resected liver due to hepatocellular carcinoma (HCC). A total of 184 patients that received curative surgery for HCC related to the hepatitis B virus at Barcelona Clinic Liver Cancer stage 0–A, and had a METAVIR fibrosis score of 4 were investigated. LSM significantly decreased after antiviral therapy during follow-up ( p = 0.001), and achieving LSM ≤8 kilopascal (kPa) suggested a reduced risk of late recurrence (12 months) (hazard ratio (HR), 0.519; 95% confidence interval (CI), 0.307–0.877; p = 0.014). Older age at surgery (≥45 years) and multiple HCC nodules predicted an increased risk of late recurrence (HR, 3.270; 95% CI, 1.296–8.251; p = 0.012; and HR, 3.146; 95% CI, 1.396–7.089; p = 0.006). Decreased LSM also suggested decreased mortality (HR, 0.251; 95% CI, 0.086–0.756; p = 0.045) along with baseline low aspartate aminotransferase-to-platelet ratio index (APRI) score (1.5) (HR, 0.251; 95% CI, 0.086–0.759; p = 0.041). Having early HCC recurrence (HR, 9.416; 95% CI, 3.566–24.861; p 0.001) and microvascular tumor invasion (HR, 3.191; 95% CI, 1.188–8.568; p = 0.021) predicted increased mortality. Among HCC patients with liver cirrhosis under antiviral therapy, achieving low LSM (≤8 kPa) predicted reduced late HCC recurrence.
机译:肝纤维化的严重程度可以通过使用瞬时弹性成像技术测量肝硬度(LS)进行无创评估。这项研究旨在评估在肝细胞癌(HCC)切除的肝硬化患者中实现低肝硬度测量(LSM)的预后价值。在巴塞罗那临床肝癌0–A期,总共184例接受了与乙肝病毒相关的HCC根治性手术且METAVIR纤维化评分为4的患者进行了调查。随访期间,抗病毒治疗后LSM显着降低(p = 0.001),并且LSM≤8千帕(kPa)提示晚期复发风险(> 12个月)降低(危险比(HR)为0.519; 95%置信区间(CI),0.307-0.877; p = 0.014)。手术年龄较大(≥45岁)和多个HCC结节预示了晚期复发的风险增加(HR,3.270; 95%CI,1.296-8.251; p = 0.012; HR,3.146; 95%CI,1.396-7.089; p = 0.006)。 LSM降低还提示死亡率降低(HR,0.251; 95%CI,0.086-0.756; p = 0.045),以及基线低天冬氨酸转氨酶与血小板比率指数(APRI)得分(<1.5)(HR,0.251; 95% CI,0.086-0.759; p = 0.041)。早期HCC复发(HR,9.416; 95%CI,3.566-24.861; p <0.001)和微血管肿瘤浸润(HR,3.191; 95%CI,1.188-8.568; p = 0.021)预测死亡率增加。在接受抗病毒治疗的肝硬化肝癌患者中,达到低LSM(≤8kPa)可以预测晚期肝癌复发率降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号